Dietary cholesterol increases paraoxonase 1 enzyme activity

Journal of Lipid Research

Volumn 53, Issue 11, 2012, Pages 2450-2458

  Kim, Daniel S ^a   Burt, Amber A ^a   Ranchalis, Jane E ^a   Richter, Rebecca J ^a   Marshall, Julieann K ^a   Nakayama, Karen S ^a   Jarvik, Ella R ^a   Eintracht, Jason F ^b   Rosenthal, Elisabeth A ^a   Furlong, Clement E ^a   Jarvik, Gail P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Cholesterol dietary; Diet; Dietary lipids; Folate; Iron; LDL oxidation antioxidants; nutrition; Vitamin C

Indexed keywords

ALCOHOL; ARYLDIALKYLPHOSPHATASE 1; ASCORBIC ACID; CHOLESTEROL; FOLIC ACID; IRON;

AGED; ARTICLE; CHOLESTEROL INTAKE; CONTROLLED STUDY; ENZYME ACTIVITY; FEEDING BEHAVIOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL INTAKE; MUTATOR GENE; NUTRITIONAL VALUE; PARAOXONASE 1 GENE; PREDICTION; PRIORITY JOURNAL;

AGED; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; CHOLESTEROL, DIETARY; ENZYME ACTIVATION; FEMALE; GENOTYPE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED;

EID: 84867360713     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P030601     Document Type: Article

References (93)

1. Gotto, A. M., Jr., and E. A. Brinton. 2004. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J. Am. Coll. Cardiol. 43: 717-724.
2. Stein, O., Y. Dabach, G. Hollander, M. Ben-Naim, G. Halperin, J. L. Breslow, and Y. Stein. 1997. Delayed loss of cholesterol from a localized lipoprotein depot in apolipoprotein A-I-deficient mice. Proc. Natl. Acad. Sci. USA. 94: 9820-9824. (Pubitemid 27408148)
3. Haase, C. L., A. Tybjaerg-Hansen, A. A. Qayyum, J. Schou, B. G. Nordestgaard, and R. Frikke-Schmidt. 2012. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J. Clin. Endocrinol. Metab. 97: E248-E256.
4. Voight, B. F., G. M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M. K. Jensen, G. Hindy, H. Holm, E. L. Ding, T. Johnson, et al. 2012. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 380: 472-580.
5. Barkowski, R. S., and W. H. Frishman. 2008. HDL metabolism and CETP inhibition. Cardiol. Rev. 16: 154-162. (Pubitemid 351549677)
6. AIM-HIGH Investigators, W. E. Boden, J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267.
7. Mackness, M. I., B. Mackness, and P. N. Durrington. 2002. Paraoxonase and coronary heart disease. Atheroscler. Suppl. 3: 49-55. (Pubitemid 38234486)
8. Jarvik, G. P., L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler. Thromb. Vasc. Biol. 20: 2441-2447.
9. Jarvik, G. P., T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. 2003. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 1465-1471. (Pubitemid 36994538)
10. Mackness, M. I., S. Arrol, C. Abbott, and P. N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104: 129-135. (Pubitemid 24035640)
11. Graham, A., D. G. Hassall, S. Rafique, and J. S. Owen. 1997. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 135: 193-204. (Pubitemid 28015186)
12. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high-density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
13. Cao, H., A. Girard-Globa, F. Berthezene, and P. Moulin. 1999. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J. Lipid Res. 40: 133-139. (Pubitemid 29022595)
14. Shih, D. M., L. Gu, Y-R. Xia, M. Navab, W-F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287. (Pubitemid 28335041)
15. Shih, D. M., Y-R. Xia, X-P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, et al. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527-17535. (Pubitemid 30430794)
16. Besler, C., K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, D. M. Shih, A. Chroni, K. Yonekawa, S. Stein, N. Schaefer, et al. 2011. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 121: 2693-2708.
17. Costa, L. G., B. E. McDonald, S. D. Murphy, G. S. Omenn, R. J. Richter, A. G. Motulsky, and C. E. Furlong. 1990. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol. Appl. Pharmacol. 103: 66-76. (Pubitemid 20115985)
18. Richter, R. J., G. P. Jarvik, and C. E. Furlong. 2008. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ. Cardiovasc. Genet. 1: 147-152.
19. Richter, R. J., G. P. Jarvik, and C. E. Furlong. 2009. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol. Appl. Pharmacol. 235: 1-9.
20. Furlong, C. E., N. Holland, R. J. Richter, A. Bradman, A. Ho, and B. Eskenazi. 2006. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genomics. 16: 183-190.
21. Richter, R. J., G. P. Jarvik, and C. E. Furlong. 2010. Paraoxonase 1 status as a risk factor for disease or exposure. Adv. Exp. Med. Biol. 660: 29-35.
22. Brophy, V. H., M. Hastings, J. B. Clendenning, R. J. Richter, G. P. Jarvik, and C. E. Furlong. 2001. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics. 11: 77-84. (Pubitemid 32108664)
23. Kim, D. S., A. A. Burt, J. E. Ranchalis, R. J. Richter, J. Marshall, J. F. Eintracht, E. A. Rosenthal, C. E. Furlong, and G. P. Jarvik. 2012. Additional common polymorphisms in the PON gene cluster predict PON1 activity but not vascular disease. J. Lipids. 2012: 476316.
24. Jarvik, G. P., R. Jampsa, R. J. Richter, C. Carlson, M. Rieder, D. Nickerson, and C. E. Furlong. 2003. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics. 13: 291-295. (Pubitemid 36583997)
25. James, R. W., I. Leviev, and A. Righetti. 2000. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation. 101: 2252-2257. (Pubitemid 30317126)
26. van der Gaag, M. S., A. van Tol, L. M. Scheek, R. W. James, R. Urgert, G. Schaafsma, and H. F. J. Hendriks. 1999. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis. 147: 405-410. (Pubitemid 29512273)
27. Sierksma, A., M. S. van der Gaag, A. van Tol, R. W. James, and H. F. Hendriks. 2002. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol. Clin. Exp. Res. 26: 1430-1435.
28. Rao, M. N., P. Marmillot, M. Gong, D. A. Palmer, L. B. Seeff, D. B. Strader, and M. R. Lakshman. 2003. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism. 52: 1287-1294. (Pubitemid 37351096)
29. Marsillach, J., N. Ferre, M. C. Vila, A. Lligona, B. Mackness, M. Mackness, R. Deulofeu, R. Sola, A. Pares, J. Pedro-Botet, et al. 2007. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin. Biochem. 40: 645-650. (Pubitemid 46839097)
30. Sutherland, W. H. F., R. J. Walker, S. A. de Jong, A. M. van Rij, V. Phillips, and H. L. Walker. 1999. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler. Thromb. Vasc. Biol. 19: 1340-1347. (Pubitemid 29227656)
31. Wallace, A. J., W. H. Sutherland, J. I. Mann, and S. M. Williams. 2001. The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes. Eur. J. Clin. Nutr. 55: 951-958. (Pubitemid 33040091)
32. Tomás, M., M. Senti, R. Elosua, J. Vila, J. Sala, R. Masia, and J. Marrugat. 2001. Interaction between the Gln Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. Eur. J. Pharmacol. 432: 121-128.
33. Tomás, M., M. Senti, F. Garcia-Faria, J. Vila, A. Torrents, M. Covas, and J. Marrugat. 2000. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 20: 2113-2119.
34. van Wijk, J., B. Coll, M. C. Cabezas, E. Koning, J. Camps, T. Rabelink, B. Mackness, and J. Joven. 2006. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin. Exp. Pharmacol. Physiol. 33: 1134-1137. (Pubitemid 44923898)
35. Wójcicka, G., A. Jamroz-Wisniewska, A. Marciniak, E. Lowicka, and J. Beltowski. 2010. The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity. Life Sci. 87: 126-132.
36. Mackness, B., M. I. Mackness, S. Arrol, W. Turkie, K. Julier, B. Abuasha, J. E. Miller, A. J. M. Boulton, and P. N. Durrington. 1998. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 139: 341-349. (Pubitemid 28361819)
37. Koren-Gluzer, M., M. Aviram, E. Meilin, and T. Hayek. 2011. The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates B-cell insulin release. Atherosclerosis. 219: 510-518.
38. Jarvik, G. P., N. T. Tsai, L. A. McKinstry, R. Wani, V. H. Brophy, R. J. Richter, G. D. Schellenberg, P. J. Heagerty, T. S. Hatsukami, and C. E. Furlong. 2002. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler. Thromb. Vasc. Biol. 22: 1329-1333. (Pubitemid 34875745)
39. Gursu, M. F., M. Onderci, F. Gulcu, and K. Sahin. 2004. Effect of vitamin C and folic acid supplementation on serum paraoxonase activity and metabolites induced by heat stress in vivo. Nutr. Res. 24: 157-164. (Pubitemid 38230397)
40. Tsakiris, S., G. A. Karikas, T. Parthimos, T. Tsakiris, C. Bakogiannis, and K. H. Schulpis. 2009. Alpha-tocopherol supplementation prevents the exercise-induced reduction of serum paraoxonase 1/arylesterase activities in healthy individuals. Eur. J. Clin. Nutr. 63: 215-221.
41. Ronald, J., R. Rajagopalan, J. Ranchalis, J. Marshall, T. Hatsukami, P. Heagerty, and G. Jarvik. 2009. Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease. Lipids Health Dis. 8: 52.
42. Rimm, E. B., M. J. Stampfer, G. A. Colditz, E. Giovannucci, and W. C. Willett. 1990. Effectiveness of various mailing strategies among nonrespondents in a prospective cohort study. Am. J. Epidemiol. 131: 1068-1071. (Pubitemid 20178628)
43. Rimm, E. B., E. L. Giovannucci, M. J. Stampfer, G. A. Colditz, L. B. Litin, and W. C. Willett. 1992. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am. J. Epidemiol. 135: 1114-1126, discussion 1127-1136.
44. Brophy, V. H., R. L. Jampsa, J. B. Clendenning, L. A. McKinstry, G. P. Jarvik, and C. E. Furlong. 2001. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 68: 1428-1436. (Pubitemid 32510618)
45. Bachorik, P. S., and J. J. Albers. 1986. Precipitation methods for quantification of lipoproteins. Methods Enzymol. 129: 78-100. (Pubitemid 16055941)
46. Warnick, G. R. 1986. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 129: 101-123. (Pubitemid 16055942)
47. Warnick, G. R., J. Benderson, and J. J. Albers. 1982. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density- lipoprotein cholesterol. Clin. Chem. 28: 1379-1388. (Pubitemid 12125081)
48. Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-502.
49. Dixon, W. J., and J. W. Tukey. 1968. Approximate behavior of the distribution of Winsorized t (Trimming/Winsorization 2). Technometrics. 10: 83-98.
50. Djoussé, L., R. C. Ellison, A. Beiser, A. Scaramucci, R. B. D'Agostino, and P. A. Wolf. 2002. Alcohol consumption and risk of ischemic stroke: The Framingham Study. Stroke. 33: 907-912.
51. Djoussé, L., J. F. Dorgan, Y. Zhang, A. Schatzkin, M. Hood, R. B. D'Agostino, D. L. Copenhafer, B. E. Kreger, and R. C. Ellison. 2002. Alcohol consumption and risk of lung cancer: The Framingham Study. J. Natl. Cancer Inst. 94: 1877-1882.
52. Carlson, C. S., P. J. Heagerty, T. S. Hatsukami, R. J. Richter, J. Ranchalis, J. Lewis, T. J. Bacus, L. A. McKinstry, G. D. Schellenberg, M. Rieder, et al. 2006. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease. J. Lipid Res. 47: 1014-1024.
53. Deakin, S., I. Leviev, S. Guernier, and R. W. James. 2003. Simvastatin modulates expression of the pon1 gene and increases serum paraoxonase. Arterioscler. Thromb. Vasc. Biol. 23: 2083-2089.
54. Manolio, T. A., T. A. Pearson, N. K. Wenger, E. Barrett-Connor, G. H. Payne, and W. R. Harlan. 1992. Cholesterol and heart disease in older persons and women review of an NHLBI workshop. Ann. Epidemiol. 2: 161-176.
55. Riedmaier, S., K. Klein, S. Winter, U. Hofmann, M. Schwab, and U. Zanger. 2011. Paraoxonase (PON1 and PON3) polymorphisms: impact on liver expression and atorvastatin-lactone hydrolysis. Front. Pharmacol. 2: 41.
56. Stoltz, D. A., E. A. Ozer, P. J. Taft, M. Barry, L. Liu, P. J. Kiss, T. O. Moninger, M. R. Parsek, and J. Zabner. 2008. Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1. J. Clin. Invest. 118: 3123-3131.
57. Ozer, E. A., A. Pezzulo, D. M. Shih, C. Chun, C. E. Furlong, A. J. Lusis, E. P. Greenberg, and J. Zabner. 2005. Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol. Lett. 253: 29-37. (Pubitemid 41605391)
58. Carmine, A., S. Buervenich, O. Sydow, M. Anvret, and L. Olson. 2002. Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov. Disord. 17: 764-766. (Pubitemid 41295021)
59. Kondo, I., and M. Yamamoto. 1998. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 806: 271-273. (Pubitemid 29010502)
60. Akhmedova, S. N., A. K. Yakimovsky, and E. I. Schwartz. 2001. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J. Neurol. Sci. 184: 179-182. (Pubitemid 32178272)
61. Dasgupta, S., F. Y. Demirci, A. Dressen, A. Kao, E. Rhew, R. Ramsey-Goldman, S. Manzi, C. Kammerer, and M. I. Kamboh. 2011. Association analysis of PON2 genetic variants with serum paraoxonase activity and systemic lupus erythematosus. BMC Med. Genet. 12: 7.
62. Kiss, E., I. Seres, T. Tarr, Z. Kocsis, G. Szegedi, and G. Paragh. 2007. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1108: 83-91. (Pubitemid 47528720)
63. Tripi, L. M., S. Manzi, Q. Chen, M. Kenney, P. Shaw, A. Kao, F. Bontempo, C. Kammerer, and M. I. Kamboh. 2006. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum. 54: 1928-1939. (Pubitemid 43877942)
64. Saadat, M. 2011. Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: a meta-analysis. Cancer Epidemiol. 36: e101-e103.
65. Liu, C., and L. Liu. 2011. Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis. Tumour Biol. 32: 1233-1240.
66. Ates, O., S. Azizi, H. H. Alp, A. Kiziltunc, S. Beydemir, E. Cinici, I. Kocer, and O. Baykal. 2009. Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J. Exp. Med. 217: 17-22.
67. Baird, P. N., D. Chu, E. Guida, H. T. V. Vu, and R. Guymer. 2004. Association of the M55L and Q192R paraoxonase gene polymorphisms with age-related macular degeneration. Am. J. Ophthalmol. 138: 665-666. (Pubitemid 39420506)
68. Baskol, G., S. Karakucuk, A. Oner, M. Baskol, D. Kocer, E. Mirza, R. Saraymen, and M. Ustdal. 2006. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica. 220: 12-16. (Pubitemid 41832689)
69. Brión, M., M. Sanchez-Salorio, M. Cortón, M. de la Fuente, B. Pazos, M. Othman, A. Swaroop, G. Abecasis, B. Sobrino, A. Carracedo, et al. 2011. Genetic association study of age-related macular degeneration in the Spanish population. Acta Ophthalmol. 89: e12-e22.
70. Esfandiary, H., U. Chakravarthy, C. Patterson, I. Young, and A. Hughes. 2005. Association study of detoxification genes in age related macular degeneration. Br. J. Ophthalmol. 89: 470-474. (Pubitemid 40469968)
71. Javadzadeh, A., A. Ghorbanihaghjo, E. Bahreini, N. Rashtchizadeh, H. Argani, and S. Alizadeh. 2011. Serum paraoxonase phenotype distribution in exudative age-related macular degeneration and its relationship to homocysteine and oxidized low-density lipoprotein. Retina. 32: 658-666.
72. Pauer, G. J. T., G. M. Sturgill, N. S. Peachey, and S. A. Hagstrom. 2010. Protective effect of paraoxonase 1 gene variant Gln192Arg in age-related macular degeneration. Am. J. Ophthalmol. 149: 513-522.
73. Rainwater, D. L., M. C. Mahaney, X. L. Wang, J. Rogers, L. A. Cox, and J. L. VandeBerg. 2005. Determinants of variation in serum paraoxonase enzyme activity in baboons. J. Lipid Res. 46: 1450-1456. (Pubitemid 43109809)
74. Galgani, J. E., R. D. Uauy, C. A. Aguirre, and E. O. Diaz. 2008. Effect of the dietary fat quality on insulin sensitivity. Br. J. Nutr. 100: 471-479.
75. Garige, M., M. Gong, R. Varatharajalu, and M. R. Lakshman. 2010. Quercetin up-regulates paraoxonase 1 gene expression via sterol regulatory element binding protein 2 that translocates from the endoplasmic reticulum to the nucleus where it specifically interacts with sterol responsive element-like sequence in paraoxonase 1 promoter in HuH7 liver cells. Metabolism. 59: 1372-1378.
76. Moon, J., S. M. Lee, H. J. Do, Y. Cho, J. H. Chung, and M. J. Shin. Quercetin up-regulates LDL receptor expression in HepG2 cells. Phytother. Res. Epub ahead of print. March 3, 2012; doi:10.1002/ptr.4646.
77. Augusti, P. R., A. R. Ruviaro, A. Quatrin, S. Somacal, G. M. Conterato, J. T. Vicentini, M. M. Duarte, and T. Emanuelli. 2012. Imbalance in superoxide dismutase/thioredoxin reductase activities in hypercholesterolemic subjects: relationship with low density lipoprotein oxidation. Lipids Health Dis. 11: 79.
78. Mahrooz, A., M. Zargari, O. Sedighi, H. Shaygani, and G. Gohari. 2012. Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis. Clin. Invest. Med. 35: E144-E151.
79. Koc, A., M. Cengiz, Z. C. Ozdemir, and H. Celik. 2012. Paraoxonase and arylesterase activities in children with iron deficiency anemia and vitamin B12 deficiency anemia. Pediatr. Hematol. Oncol. 29: 345-353.
80. Aslan, M., M. Kosecik, M. Horoz, S. Selek, H. Celik, and O. Erel. 2007. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis. 191: 397-402. (Pubitemid 46400702)
81. Martinovi, J., J. Kotur-Stevuljevic, V. Dopsaj, M. Dopsaj, A. Stefanovic, and G. Kasum. 2010. Paraoxonase activity in athletes with depleted iron stores and iron-deficient erythropoiesis. Clin. Biochem. 43: 1225-1229.
82. Pla, A., L. Rodrigo, A. F. Hernandez, F. Gil, and O. Lopez. 2007. Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem. Biol. Interact. 167: 63-70. (Pubitemid 46413237)
83. Gonzalvo, M. C., F. Gil, A. F. Hernandez, E. Villanueva, and A. Pla. 1997. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem. Biol. Interact. 105: 169-179. (Pubitemid 27353307)
84. Gençer, N., and O. Arslan. 2009. Purification human PON1Q192 and PON1R192 isoenzymes by hydrophobic interaction chromatography and investigation of the inhibition by metals. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877: 134-140.
85. Ekinci, D., and S. Beydemir. 2010. Purification of PON1 from human serum and assessment of enzyme kinetics against metal toxicity. Biol. Trace Elem. Res. 135: 112-120.
86. Nguyen, S. D., N. D. Hung, P. Cheon-Ho, K. M. Ree, and S. Dai-Eun. 2009. Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochim. Biophys. Acta. 1790: 155-160.
87. Ayub, A., M. I. Mackness, S. Arrol, B. Mackness, J. Patel, and P. N. Durrington. 1999. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 19: 330-335. (Pubitemid 29072747)
88. Navab, M., G. M. Anantharamaiah, S. Hama, D. W. Garber, M. Chaddha, G. Hough, R. Lallone, and A. M. Fogelman. 2002. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105: 290-292. (Pubitemid 34106174)
89. Osaki, F., Y. Ikeda, T. Suehiro, K. Ota, S. Tsuzura, K. Arii, Y. Kumon, and K. Hashimoto. 2004. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis. 176: 279-287. (Pubitemid 39369517)
90. de Oliveira Otto, M. C., A. Alonso, D. H. Lee, G. L. Delclos, A. G. Bertoni, R. Jiang, J. A. Lima, E. Symanski, D. R. Jacobs, Jr., and J. A. Nettleton. 2012. Dietary intakes of zinc and heme iron from red meat, but not from other sources, are associated with greater risk of metabolic syndrome and cardiovascular disease. J. Nutr. 142: 526-533.
91. Flesch, M., S. Rosenkranz, E. Erdmann, and M. Bohm. 2001. Alcohol and the risk of myocardial infarction. Basic Res. Cardiol. 96: 128-135. (Pubitemid 32236781)
92. Miller 3rd, E. R., S. Juraschek, R. Pastor-Barriuso, L. A. Bazzano, L. J. Appel, and E. Guallar. 2010. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am. J. Cardiol. 106: 517-527.
93. Rock, W., M. Rosenblat, R. Miller-Lotan, A. P. Levy, M. Elias, and M. Aviram. 2008. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J. Agric. Food Chem. 56: 8704-8713.